TEKTURNA HCT
LOE Approachingaliskiren hemifumarate; hydrochlorothiazide
NDAORALTABLET
Approved
Jan 2008
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEKTURNA HCT is a fixed-dose oral tablet combining aliskiren (a direct renin inhibitor) and hydrochlorothiazide (a thiazide diuretic) for the treatment of hypertension. This combination targets two distinct pathways in blood pressure regulation, offering complementary mechanisms for enhanced antihypertensive efficacy. The product is indicated for patients requiring dual-agent therapy to achieve blood pressure control.
$0.388MPart D
LOE Approaching1.7 years to LOEDeclining commercial footprint with minimal recent utilization signals a shrinking market opportunity and reduced team expansion prospects.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.